Chemokines

Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthmaIn VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)

Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthmaIn VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)

ML339 is a potent and selective CXCR6 ( IC 50 of 140 nM) antagonist that is selective (IC 50 &gt79 μM) against CXCR5, CXCR4 , CCR6 and Apelin receptor (APJ) . ML339 holds potential to advance the field of prostate cancer researchForm:SolidIC50&amp

ML339 is a potent and selective CXCR6 ( IC 50 of 140 nM) antagonist that is selective (IC 50 &gt79 μM) against CXCR5, CXCR4 , CCR6 and Apelin receptor (APJ) . ML339 holds potential to advance the field of prostate cancer researchForm:SolidIC50&amp

ML339 is a potent and selective CXCR6 ( IC 50 of 140 nM) antagonist that is selective (IC 50 &gt79 μM) against CXCR5, CXCR4 , CCR6 and Apelin receptor (APJ) . ML339 holds potential to advance the field of prostate cancer researchIC50&amp

NBI-74330 is a potent antagonist for CXCR3 , and exhibits potent inhibition of ( 125 I)CXCL10 and ( 125 I)CXCL11 specific binding with K i of 1.5 and 3.2 nM, respectively.In VitroBI-74330 demonstrates potent inhibition of [ 125 I]CXCL11 specific

NBI-74330 is a potent antagonist for CXCR3 , and exhibits potent inhibition of ( 125 I)CXCL10 and ( 125 I)CXCL11 specific binding with K i of 1.5 and 3.2 nM, respectively.In VitroBI-74330 demonstrates potent inhibition of [ 125 I]CXCL11 specific

NBI-74330 is a potent antagonist for CXCR3 , and exhibits potent inhibition of ( 125 I)CXCL10 and ( 125 I)CXCL11 specific binding with K i of 1.5 and 3.2 nM, respectively.In VitroBI-74330 demonstrates potent inhibition of [ 125 I]CXCL11 specific

NBI-74330 is a potent antagonist for CXCR3 , and exhibits potent inhibition of ( 125 I)CXCL10 and ( 125 I)CXCL11 specific binding with K i of 1.5 and 3.2 nM, respectively.In VitroBI-74330 demonstrates potent inhibition of [ 125 I]CXCL11 specific

NBI-74330 is a potent antagonist for CXCR3 , and exhibits potent inhibition of ( 125 I)CXCL10 and ( 125 I)CXCL11 specific binding with K i of 1.5 and 3.2 nM, respectively.In VitroBI-74330 demonstrates potent inhibition of [ 125 I]CXCL11 specific

NBI-74330 is a potent antagonist for CXCR3 , and exhibits potent inhibition of ( 125 I)CXCL10 and ( 125 I)CXCL11 specific binding with K i of 1.5 and 3.2 nM, respectively.In VitroBI-74330 demonstrates potent inhibition of [ 125 I]CXCL11 specific

NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 ( HY-10046 ) NUCC-390 dihydrochloride promotes nerve